Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Bruera · SciRah

Researcher profile · Semantic Scholar

G. Bruera

Share profile

G. Bruera — researcher profile on SciRah

h-index: 14
Works: 73
Citations: 593

Most-cited papers

General principles of chemotherapy.
E. Ricevuto, G. Bruera, P. Marchetti
2010European Review for Medical and Pharmacological Sciences70 citations
Semantic Scholar
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
F. Marampon, G. Gravina, V. M. Popov, L. Scarsella +10 more
2014International Journal of Oncology49 citations Open access
Semantic Scholar
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
G. Bruera, A. Santomaggio, K. Cannita, P. L. Baldi +7 more
2010BMC Cancer46 citations Open access
Semantic Scholar
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
G. Bruera, K. Cannita, F. Giuliante, P. L. Baldi +6 more
2012Clinical colorectal cancer27 citations
Semantic Scholar
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy
G. Bruera, E. Ricevuto
2011Expert Opinion on Biological Therapy26 citations
Semantic Scholar
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
G. Bruera, K. Cannita, A. Tessitore, A. Russo +3 more
2015Critical reviews in oncology/hematology25 citations Open access
Semantic Scholar
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
M. F. Morelli, A. Santomaggio, Enrico Ricevuto, K. Cannita +15 more
2010Oncology Report25 citations Open access
Semantic Scholar
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
G. Bruera, K. Cannita, Daniela Di Giacomo, A. Lamy +6 more
2013BMC Medicine24 citations Open access
Semantic Scholar
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
G. Bruera, K. Cannita, Daniela Di Giacomo, A. Lamy +8 more
2012BMC Medicine24 citations Open access
Semantic Scholar
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
G. Bruera, F. Pepe, U. Malapelle, P. Pisapia +5 more
2018OncoTarget21 citations Open access
Semantic Scholar
Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.
C. Ficorella, G. Bruera, K. Cannita, G. Porzio +4 more
2012Clinical colorectal cancer21 citations
Semantic Scholar
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study
S. Guadagni, M. Clementi, A. Mackay, E. Ricevuto +9 more
2020Journal of Cancer Research and Clinical Oncology18 citations Open access
Semantic Scholar
Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease.
M. Leopardi, Evelina Di Marco, A. Musilli, E. Ricevuto +2 more
2017Annals of Vascular Surgery17 citations
Semantic Scholar
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clin
G. Bruera, A. Giuliani, L. Romano, A. Chiominto +6 more
2019BMC Cancer15 citations Open access
Semantic Scholar
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2013BioMed Research International14 citations Open access
Semantic Scholar
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
S. Guadagni, G. Fiorentini, M. De Simone, F. Masedu +9 more
2019Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
G. Bruera, A. Russo, A. Galvano, S. Rizzo +1 more
2016OncoTarget13 citations Open access
Semantic Scholar
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2014International Journal of Oncology12 citations Open access
Semantic Scholar
Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
S. Guadagni, G. Fiorentini, A. Mambrini, F. Masedu +8 more
2019OncoTarget11 citations Open access
Semantic Scholar
Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
G. Bruera, K. Cannita, A. Giordano, R. Manetta +7 more
2014BioMed Research International11 citations Open access
Semantic Scholar
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
G. Bruera, K. Cannita, A. Giordano, R. Vicentini +2 more
2013International Journal of Oncology11 citations Open access
Semantic Scholar
Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
A. Irelli, G. Bruera, K. Cannita, Eleonora Palluzzi +4 more
2014BioMed Research International10 citations Open access
Semantic Scholar
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
G. Bruera, E. Ricevuto
2020Frontiers in Oncology8 citations Open access
Semantic Scholar
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
G. Bruera, S. Massacese, F. Pepe, U. Malapelle +6 more
2019Therapeutic Advances in Medical Oncology8 citations Open access
Semantic Scholar
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
A. Tessitore, G. Bruera, Valentina Mastroiaco, K. Cannita +8 more
2018Human Pathology8 citations
Semantic Scholar
Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
E. Ricevuto, V. Cocciolone, M. Mancini, K. Cannita +8 more
2015The Oncologist8 citations Open access
Semantic Scholar
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
G. Bruera, E. Ricevuto
2020Pharmacogenomics and Personalized Medicine6 citations Open access
Semantic Scholar
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases
S. Guadagni, F. Masedu, G. Fiorentini, D. Sarti +11 more
2022BMC Cancer5 citations Open access
Semantic Scholar
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
S. Guadagni, A. Farina, L. Cappabianca, Michela Sebastiano +9 more
2020International Journal of Molecular Sciences5 citations Open access
Semantic Scholar
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
G. Bruera, S. Massacese, A. Galvano, A. Dal Mas +5 more
2018OncoTarget5 citations Open access
Semantic Scholar
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
G. Bruera, S. Massacese, S. Candria, A. Galvano +7 more
2018OncoTarget4 citations Open access
Semantic Scholar
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.
M. Tudini, Eleonora Palluzzi, K. Cannita, M. Mancini +6 more
2011Oncology Report4 citations Open access
Semantic Scholar
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice
G. Bruera, F. Pepe, U. Malapelle, M. di Staso +10 more
2021Annals of Translational Medicine3 citations Open access
Semantic Scholar
Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
G. Bruera, M. di Staso, P. Bonfili, A. Galvano +8 more
2018OncoTarget3 citations Open access
Semantic Scholar
"Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study.
A. Santomaggio, E. Ricevuto, K. Cannita, G. Bruera +6 more
2016Journal of Clinical Oncology3 citations
Semantic Scholar
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
G. Bruera, A. D'Andrilli, M. Simmaco, S. Guadagni +2 more
2020Frontiers in Oncology2 citations Open access
Semantic Scholar
Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
G. Bruera, K. Cannita, Daniela Di Giacomo, A. Lamy +8 more
2012Journal of Clinical Oncology2 citations
Semantic Scholar
Predictive and prognostic implications of KRAS genotype in patients with metastatic colorectal cancer (MCRC) treated with FIr-B/FOx association.
G. Bruera, K. Cannita, D. Di Giacomo, G. Troncone +6 more
2011Journal of Clinical Oncology2 citations
Semantic Scholar
[Effect of etomidate, flunitrazepam and ketamine on the brainstem auditory evoked potentials of surgical patients without audiological or neurological changes].
G. Bertoldi, E. Manno, G. Bruera, M. Gilli +1 more
1983Minerva Anestesiologica2 citations
Semantic Scholar
PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice
Enrico Ricevuto, Celeste Morgani, Fabrizia Seri, G. Bruera
2024Asian Journal of Andrology1 citations Open access
Semantic Scholar
Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.
G. Bruera, F. Pepe, U. Malapelle, P. Pisapia +5 more
20171 citations
Semantic Scholar
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.
G. Bruera, F. Pepe, U. Malapelle, P. Pisapia +5 more
2017Annals of Oncology1 citations Open access
Semantic Scholar
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
G. Bruera, U. Malapelle, F. Pepe, P. Pisapia +4 more
20171 citations
Semantic Scholar
P043 Bevacizumab/paclitaxel as first line therapy for metastatic breast cancer: new schedule in real life
K. Cannita, S. Paradisi, V. Cocciolone, L. Rinaldi +6 more
20151 citations Open access
Semantic Scholar
R19Temozolomide dose-dense regimen in high grade gliomas: dose-finding/phase II study
Luca Napoleoni, G. Bruera, M. Adinolfi, A. Catalucci +6 more
20151 citations Open access
Semantic Scholar
Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression.
G. Bruera, K. Cannita, Daniela Di Giacomo, A. Lamy +9 more
20131 citations
Semantic Scholar
Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to KRAS genotype and disease extension.
G. Bruera, K. Cannita, D. Di Giacomo, A. Lamy +6 more
20121 citations Open access
Semantic Scholar
Effectiveness of FIr-B/FOx and liver metastasectomies in liver-only metastatic colorectal cancer (MCRC).
G. Bruera, K. Cannita, P. L. Baldi, A. Santomaggio +5 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
Clinical properness of poker schedule weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-B/FOx) in young-elderly metastatic colorectal cancer (MCRC).
G. Bruera, A. Santomaggio, K. Cannita, P. L. Baldi +6 more
20101 citations
Semantic Scholar
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma
M. Lapecorella, M. Napolitano, M. Tudini, G. Bruera +4 more
2010Haemophilia1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Ricevuto×46
Invite
E. Ricevuto — researcher profile on SciRah
C. Ficorella×25
Invite
C. Ficorella — researcher profile on SciRah
K. Cannita×23
Invite
K. Cannita — researcher profile on SciRah
A. Dal Mas×11
Invite
A. Dal Mas — researcher profile on SciRah

×9

Invite

G. Troncone — researcher profile on SciRah

Invite

P. L. Baldi — researcher profile on SciRah

Invite

S. Guadagni — researcher profile on SciRah

Invite

A. Giordano — researcher profile on SciRah

R. Vicentini×7

Invite

R. Vicentini — researcher profile on SciRah

Invite

G. Calvisi — researcher profile on SciRah

A. Santomaggio×6

Invite

A. Santomaggio — researcher profile on SciRah

Daniela Di Giacomo×6

Invite

Daniela Di Giacomo — researcher profile on SciRah